Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture

Inclusion Criteria: New brittle hip fractures; New brittle vertebral fractures; New other site fractures and/or total hip or neck of femur or L1-L4 T-value < -1.0; Men or postmenopausal women; Age 45-90 years old; Ability to move autonomously Exclusion Criteria: bone metabolic diseases except for osteoporosis eg. a. (Osteogenesis Imperfecta, Paget's disease, Osteomalacia), b. Cushing's syndrome, c.hyperprolactinemia; Having primary hyperparathyroidism or hypothyroidism; Had or have osteomyelitis of the jaw or necrosis of the jaw; GFR<30ml/min/1.73m2; Active infection that requires systematic treatment; Used intravenous bisphosphonate, fluoride, or strontium for osteoporosis within 2 years; Used teriparatide and denosumab for osteoporosis within 6 months; The time gap between the first time and the last time oral bisphosphonate for osteoporosis less than 1 year; Patients with malignant tumors or bone metastases within 5 years, except tumors that are expected to be cured after treatment; Have hypocalcemia and hypercalcemia; Unexplained elevation of alkaline phosphatase; A serious deficiency of vitamin D (25OHD <10ng/mL); Patients who have previously received external radiation or radiation therapy with bone implants; Uncontrolled comorbidities included heart failure above the New York cardiac Function Scale, glycosylated hemoglobin > 8.5%, and severe arrhythmias; Planned pregnancy and lactation at present or during the study period; Allergic to teriparatide and denosumab; Participating in clinical trials of other drugs at present; subjects do not suitable for this study